Targeted pill takes on rare skull base cancers
NCT ID NCT06176989
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the cancer stays under control and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Enasidenib (a targeted therapy pill that blocks the IDH2 mutation)
- What this could lead to
- If successful, this could offer a new treatment option for people with rare, hard-to-treat cancers of the nasal cavity or skull base that have an IDH2 mutation.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CHONDROSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug trial targets rare nasal cancer
- New hope for rare bone cancer? drug shows promise in early trial
- Triple-Drug cocktail shows promise against rare neuroendocrine tumors
- New radiation drug targets Hard-to-Treat cancers
- New combo treatment may spare head and neck cancer patients from disfiguring surgery
- Rare nasal cancer under the microscope: new study aims to unlock secrets